The growing range of treatment options for EGFR-mutated non-small cell lung cancer (NSCLC) has made first-line decisions more complex and more critical. Patients are increasingly more aware of new and different treatment options and are seeking therapies that align with their personal values. As survival outcomes continue to improve, shared decision-making (SDM) plays a vital …

Beyond Survival: Empowering a Future for Patients with EGFR-Mutated NSCLC Read More »

The post-pandemic burden of COVID-19 remains significant in adults. Four studies from IDWeek 2024 highlight the benefits of nirmatrelvir-ritonavir (NMV/r) for high-risk adults with SARS-CoV-2 immunity and link chronic conditions to COVID-19 hospitalization. Identifying high-risk patients and using NMV/r in outpatient settings can reduce severe

At the Asia Vaccines and Antivirals Summit (AVAS) 2025 held in Bangkok, Thailand, two expert-led sessions provided valuable perspectives on the expanding role of oral antivirals in COVID-19 management. Dr Daniel Griffin, an infectious disease specialist and Clinical Instructor of Medicine at Columbia University, New York, US, focused on protecting high-risk populations through the timely …

Protecting the vulnerable: The role of oral antivirals in COVID-19 management Read More »

A low-dose combination therapy, AD-209, that includes telmisartan 20 mg, amlodipine 2.5 mg, and chlorthalidone 6.25 mg demonstrates efficacy in lowering high blood pressure (BP) when compared with telmisartan alone in patients with essential hypertension, reports a study presented at ESC 2025. This multicentre, randomized, double-blinded, parallel, phase III clinical trial also notes a comparable safety profile …

Amlodipine-telmisartan-chlorthalidone combo promises better BP-lowering effect Read More »

Treatment with semaglutide and dulaglutide results in a significantly lower risk of adverse cognitive decline in patients with heart failure (HF), as shown by the results of a retrospective cohort study using real-world data. “Semaglutide and dulaglutide were associated with reduced cognitive decline in heart failure, particularly vascular dementia,” said lead author Andreas Kalogeropoulus, associate professor at …

Semaglutide, dulaglutide help prevent cognitive decline in HF patients Read More »

A recently developed model demonstrates its utility in predicting critical care entrance among children with dengue. The development and internal validation of the predictive model involved a total of 1,385 patients. In temporal validation with 519 additional participants, the c-statistic was 0.82 (95 percent confidence interval [CI], 0.77–0.87), and the calibration slope was 0.98 (95 …

New model predicts critical admission in children with dengue Read More »